Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
about
My approach to the treatment of sclerodermaCurrent perspectives on the immunopathogenesis of systemic sclerosisManagement of Systemic-Sclerosis-Associated Interstitial Lung DiseaseSystemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic reviewSystemic sclerosis disease modification clinical trials design: quo vadis?Old medications and new targeted therapies in systemic sclerosis.Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosisTreatment of Rapidly Progressive Systemic Sclerosis: Current and Futures PerspectivesTreatment of early diffuse systemic sclerosis skin disease.Systemic sclerosis--challenges for clinical practice.Early systemic sclerosis-opportunities for treatment.Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.Update on systemic sclerosis.Cytokines in the immunopathology of systemic sclerosis.Strategy for treatment of fibrosis in systemic sclerosis: Present and future.Clinical Trial Design Issues in Systemic Sclerosis: an Update.Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.Extrahepatic Manifestations of Primary Biliary Cholangitis.[Established medications : new areas of application].Enteric-coated mycophenolate sodium for progressive systemic sclerosis--a prospective open-label study with CT histography for monitoring of pulmonary fibrosis.Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
P2860
Q24618843-294A0685-B6CE-4DC6-ABA8-FC5A7BAD8B10Q26741264-87FCFD89-B5E6-41D3-B73C-388D8A19ED49Q26799573-2F1A71EC-7D8B-40B0-886F-147507E4438DQ31125829-088277CE-2885-45A5-8B3B-3444EA8D6553Q35040442-E96D0DD0-CC9E-4E3D-B323-0AD2C5FF9242Q35560664-C49EF875-F179-454C-8B69-DE7FAEAE71E1Q36067226-498FB2B2-33F3-438B-A52A-222266B0402FQ36154430-002E6766-88EF-4228-930F-7FE6ECEC23E7Q37022001-8DC2CE53-57C2-4E40-95A6-57E219E5DF04Q37381549-CF47B489-4310-4A2B-B979-300096ED959EQ37467457-5D622C71-2F88-4137-8E92-883B1CD59B16Q38059459-F532F4DC-9F19-4379-B48E-9C8B88897E07Q38364855-D9EBBBF4-2493-461D-A497-B82E8CED02D7Q38379767-90DC85D8-6FFD-4A2C-95EF-9E65053F1D26Q38542317-B45596A3-D76C-44D9-ADDC-0CFA04D444B1Q38543692-91B8903E-8F28-4B04-A2DB-0901FB6C0774Q38701990-A2446CFC-5960-419E-B1CB-7F35EEE49226Q38825869-16AD5D4C-11F0-4487-B907-F2EE521329B2Q38880396-8D5E5783-26E9-475A-A09E-A14B5DB37564Q39177903-6FAD1222-1551-45CD-8C60-D8819243D0AFQ44480906-86373A1D-2DA8-4D27-AB05-6FA6204AB1F6Q45395276-D6C78293-0153-4F67-AB8E-E2515DC3712DQ50623134-0D3A0FE6-5BEA-49BC-B0C2-5575E63B8A7F
P2860
Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term experience of mycoph ...... cutaneous systemic sclerosis.
@en
Long-term experience of mycoph ...... cutaneous systemic sclerosis.
@nl
type
label
Long-term experience of mycoph ...... cutaneous systemic sclerosis.
@en
Long-term experience of mycoph ...... cutaneous systemic sclerosis.
@nl
prefLabel
Long-term experience of mycoph ...... cutaneous systemic sclerosis.
@en
Long-term experience of mycoph ...... cutaneous systemic sclerosis.
@nl
P2093
P2860
P356
P1476
Long-term experience of mycoph ...... e cutaneous systemic sclerosis
@en
P2093
Ami A Shah
Elizabeth N Le
Francesco Boin
Fredrick M Wigley
P2860
P304
P356
10.1136/ARD.2010.142000
P407
P577
2011-03-06T00:00:00Z